Rhythm Pharmaceuticals (RYTM) Assets Average (2017 - 2026)

Rhythm Pharmaceuticals (RYTM) has 10 years of Assets Average data on file, last reported at $461.3 million in Q1 2026.

• Quarterly Assets Average rose 18.43% year-over-year to $461.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $461.3 million (up 18.43% YoY) and the FY2025 annual result came in at $436.2 million, up 20.34% from the prior year.
• Assets Average fell to $461.3 million in Q1 2026 per RYTM's latest filing, from $493.5 million in the prior quarter.
• Across five years, Assets Average topped out at $493.5 million in Q4 2025 and bottomed at $281.2 million in Q2 2022.
• The 5-year median for Assets Average is $364.1 million (2023), against an average of $365.1 million.
• The widest annual swing landed in 2022, when Assets Average plunged 30.61%; it then soared 31.72% in 2025.
• Tracing RYTM's Assets Average over 5 years: stood at $386.0 million in 2022, then declined by 11.03% to $343.5 million in 2023, then grew by 10.03% to $377.9 million in 2024, then soared by 30.59% to $493.5 million in 2025, then retreated by 6.54% to $461.3 million in 2026.
• Per Business Quant, the three latest RYTM Assets Average figures stand at $461.3 million (Q1 2026), $493.5 million (Q4 2025), and $439.8 million (Q3 2025).

Peer Comparison